Chairman of the Board, President and Chief Executive Officer of Veracyte
Bonnie Anderson is Chairman of the Board, President and Chief Executive Officer of Veracyte, a leading genomic diagnostics company that improves the lives of patients by reducing diagnostic uncertainty in healthcare, enabling patients to get diagnosed sooner and avoid risky, costly surgery that is often unnecessary. Ms. Anderson cofounded Veracyte in 2008, took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Her career spans over 30 years in regulated diagnostics and life science markets. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson has received numerous awards in her career, including being named to Fast Company’s “100 Most Creative People in Business” list (2015) and to the San Francisco Business Times’ list of the “Bay Area’s Most Admired CEOs” (2014).
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Advanced diagnostics plays a critical role in precision medicine, insuring that patients receive the most appropriate treatment. However, regulatory uncertainty as well as difficulties with reimbursement difficulty, create a challenging funding environment for innovation. This session’s discussion will focus on where the diagnostics industry is today as well as its outlook for the future.